內地19省區聯盟中成藥集採開標 價格最多跌82.6%
湖北省醫藥價格和招標採購管理服務網公示中成藥省際聯盟集中帶量採購擬中選結果顯示,從公佈的擬中選名單來看,此次共計111箇中成藥產品入選,涉及神威藥業(02877.HK)、昆藥集團(600422.SH)、康緣藥業(600557.SH)、珍寶島藥業(603567.SH)、同仁堂(600085.SH)等共97家企業。
據《人民網》報道,此次共有157家企業、182個產品參與。通過現場競爭,其中有97家企業、111個產品中選,中選率達62%,中選產品劑型規格齊全,平均降幅42.27%,最大降幅82.63%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.